share_log

BMO Capital Maintains Market Perform on CytomX Therapeutics, Lowers Price Target to $3.25

BMO Capital Maintains Market Perform on CytomX Therapeutics, Lowers Price Target to $3.25

BMO Capital維持CytomX Therapeutics的市場表現,將目標股價下調至3.25美元
Moomoo 24/7 ·  03/12 11:11

BMO Capital analyst Etzer Darout maintains CytomX Therapeutics (NASDAQ:CTMX) with a Market Perform and lowers the price target from $3.3 to $3.25.

BMO Capital分析師埃策·達魯特維持CytomX Therapeutics(納斯達克股票代碼:CTMX)的市場表現,並將目標股價從3.3美元下調至3.25美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論